MarketCap
Facebook
X
Telegram
Altimmune EBITDA | ALT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Altimmune
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -94.4 M | -103 M | -95.5 M | -87.9 M | -96.4 M | -54.5 M | -20.1 M | -17.6 M | -16 M | -11.1 M | -715 K | -10 M | -10.7 M | -5.96 M | -11.3 M | -22.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -715 K | -103 M | -41.1 M |
Quarterly EBITDA Altimmune
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.9 M | -24.2 M | - | - | - | -21.8 M | - | - | - | -26.7 M | - | - | - | -22.1 M | - | -24.7 M | -20.2 M | -19.4 M | - | -32.8 M | -24.7 M | -14.8 M | - | -18.1 M | -18.3 M | -7.23 M | - | -11.1 M | -3.43 M | -2.27 M | - | -3.91 M | -5.36 M | -5.97 M | - | -30.9 M | -3.97 M | -4.5 M | -5.51 M | -4.76 M | -1.56 M | -1.22 M | -940 K | -1.62 M | -1.93 M | 1.2 M | -2.62 M | -3.96 M | -1.13 M | -2.36 M | -5.07 M | -3.15 M | -1.44 M | -1.04 M | -1.43 M | -1.72 M | -1.38 M | -1.5 M | -1.08 M | -2.91 M | -2.96 M | -4.42 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 M | -32.8 M | -9.02 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-214 M | $ 4.2 | -0.36 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
15.8 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
228 K | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-21.4 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
4.01 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-57.9 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
-76.6 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-602 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
505 K | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
14.2 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
-37.7 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
-64.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-389 M | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
7.5 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-38.8 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
-431 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-35.9 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-45.7 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-150 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
-113 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
2 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
31.8 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
-21.6 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
-30.3 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
-13.3 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-6.09 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
-40.5 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
-2.86 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
-21.5 M | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
-139 M | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
151 M | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-645 M | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-2.17 M | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
-209 M | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
-27.7 M | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
-25.5 M | - | 8.07 % | $ 54 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Verona Pharma plc
VRNA
|
-154 M | - | - | $ 69.7 B | Britain |